Galmed Pharmaceuticals Ltd (GLMD)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Allen Baharaff |
| Employees: | 20 |
| Web site: | galmedpharma.com |
|
C/O MEITAR LAW OFFICES, 16 ABBA HILLEL SILVER RD., RAMAT GAN, L3, 5250608
97236938448
| |
| Date | Ratio |
|---|---|
| 2024-08-30 | 1:12 |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Galmed Pharmaceuticals Ltd. develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine.
Please log in first to see chart